Immunome, Inc.
IMNM
$8.49
$0.030.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 67.84% | 13.37% | -984.00% | -550.03% | -2,932.60% |
| Total Depreciation and Amortization | 176.05% | 131.52% | 243.98% | 328.66% | 77.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.70% | -61.00% | 615.55% | 789.35% | 9,179.00% |
| Change in Net Operating Assets | -479.71% | 166.74% | 138.24% | 320.22% | -83.44% |
| Cash from Operations | -374.98% | -140.91% | -296.64% | -312.79% | -146.21% |
| Capital Expenditure | -69.36% | -293.98% | -132,191.67% | -589.41% | -1,941.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 124.96% | 128.60% | -- | -- | -- |
| Cash from Investing | 113.67% | 132.52% | 67,038.89% | -23,925.88% | -35,023.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -26.06% | 5,421.56% | -- | -- | 686,958.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 25.93% | -100.73% | -100.34% | -- | -- |
| Cash from Financing | -26.07% | -63.81% | -99.50% | -- | 645,326.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.20% | -251.99% | -118.70% | -1,637.53% | 609.70% |